Opto Circuits (India), a leading manufacturer of healthcare equipments in India, has posted better performance during the third quarter and first nine months of 2008-09. The company's consolidated net sales jumped by 65.7 per cent to Rs 211.02 crore from Rs 127.33 crore in the corresponding period of last year. Its consolidated net profit increased by 47.3 per cent to Rs 52.63 crore giving a earning per share of Rs 3.29 as against Rs 2.23 in the last period.

Commenting on the performance, Vinod Ramnani, chairman & managing director, said, "Our products and marketing strategies have defied the rough times to yield us good results yet again. We have been committed to innovation and have extended that philosophy to not just product development but also to market penetration and sustenance. We expect similar dynamism and growth going forward."

The company received DCGI registration on Eurocor's drug (paclitaxel) - eluting coronary balloon dilatation catheter, DIOR. The product was recently introduced to leading Indian interventional cardiologists at a grand symposium in Mumbai and it will be distributed all over India. Its subsidiary, Eurocor GmbH, has appointed leading marketing agency, VascuMed, to distribute its cardiovascular products in the UK, which makes for an important market for the company.

For the first nine months of 2008-09, Opto Circuits' consolidated net sales increased to Rs 605.40 crore from Rs 347.60 crore in the corresponding period of last year, a growth of 74.2 per cent. Its net profit went up by 58.1 per cent to Rs 154.35 crore from Rs 97.63 crore. The company's standalone net sales for the nine months amounted to Rs 281.31 crore as against Rs 233.31 crore and it earned a net profit of Rs 100 crore as compared to Rs 83.14 crore.